Post-hoc analysis reveals clinically meaningful and statistically significant improvement in eGOS when ronopterin is infused within 12 hours after trauma vasopharm will communicate next steps after discussing these results with Competent Authorities Trial did not meet its primary endpoint Further results to be published in a peer-reviewed journal Currently there are no approved treatments for patients with moderate and severe traumatic brain injury   vasopharm GmbH, a privately-held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announces that the NOSTRA III traumatic brain injury (TBI) Phase III clinical trial of ronopterin (VAS203) did not meet the pre-specified primary endpoint of improvement in extended Glasgow Outcome Scale (eGOS) at six months after trauma. Importantly, hypothesis driven post-hoc analysis reveals a statistically significant and clinically meaningful increase in eGOS over time in patients with moderate and severe TBI when ronopterin is infused within 12 hours after trauma. The NOSTRA III trial (NO Synthase in TRAumatic Brain Injury; clinicaltrials.gov identifier NCT02794168) is a pivotal European trial assessing the efficacy and safety of ronopterin for the treatment of patients with moderate and severe TBI. Current therapeutic approaches to acute TBI are predominantly supportive measures, initiated reactively, to decrease elevated intracranial pressure with the aim of reducing mortality and morbidity. To date, no specific pharmacologic intervention has been demonstrated to improve long-term physical and cognitive recovery. The NOSTRA III trial is a placebo-controlled, randomised, double-blind, multi-centre study in five countries at 29 investigational sites in Austria, France, Germany, Spain and the UK. In total 224 eligible patients were enrolled. Ronopterin is the first drug which simultaneously targets blood vessels and tissue of the injured brain by reducing the excessive production of nitric oxide via upregulated inducible NO synthase (iNOS). Professor Dr John Stover, Chief Medical Officer of vasopharm, explained: “While NOSTRA III did not achieve statistical significance in the pre-specified primary endpoint of eGOS at six months after trauma, we performed a detailed hypothesis driven post-hoc analysis guided by pathophysiology combined with biochemistry and pharmacology. This analysis clearly reveals the potential of ronopterin to benefit patients when infused within the initial 12 hours after TBI. Ronopterin was associated with a higher median eGOS at 3 and 6 months vs placebo (3 months: eGOS 5 vs 4; 6 months: eGOS 6 vs 5, respectively), a larger proportion of patients with good recovery, i.e. eGOS 7 and 8 at 6 months (37% vs 23%), and a significantly higher odds ratio in patients with an increase in eGOS from 3 to 6 months (2.98; p=0.039). The Number Needed to Treat is calculated at 7 for patients with a good recovery (eGOS 7 and 8) and 4 for patients with an increase in eGOS over time. These post-hoc results of the NOSTRA III trial corroborate the positive results of the dose-finding NOSTRA II study. This efficacy, in the opinion of the Data Monitoring Committee, clearly outweighs the known adverse event profile, resulting in a positive benefit-risk assessment. We consider these results robust and clinically relevant, and vasopharm will seek scientific advice from Competent Authorities on the further regulatory pathway for ronopterin.” Frank Tegtmeier, PhD, Chief Scientific Officer of vasopharm, commented: “We are pleased that we have identified a clinically coherent explanation for the results of the pre-specified analysis and that we can provide a clear rationale for the beneficial use of ronopterin in patients with moderate and severe TBI. The early infusion and trajectory of improvement over time are supported by recent publications of observational studies and randomised controlled Phase III trials.” Prof. Dr. Erich Schmutzhard, Medical University of Innsbruck, Austria and Chief Investigator for the NOSTRA III trial, said:  “The demanding complexity of traumatic brain injury is well known, every injury is different. Experience shows us that not all patients will benefit from interventions and treatment approaches we deem helpful. In this difficult clinical context, it is remarkable that ronopterin resulted in a significantly higher number of patients with signs of improved recovery. Ronopterin is the first drug to potentially offer a new and advanced treatment option to patients with acute moderate and severe TBI. The early infusion will be easy to integrate in our daily emergency and intensive care routine.” NOSTRA III’s primary endpoint is the extended Glasgow Outcome Scale (eGOS) at six months post trauma; the eGOS at three months after TBI is one of the secondary endpoints. The combination of these primary and secondary endpoints allows evaluation of the trajectory of neurologic recovery during the first six months after TBI, reflecting a clinically important measure and timeframe.

250 Besucher haben beim Science4Life TechSLAM am 11. Mai 2021 via Online-Voting abgestimmt und die kreativen Pitches von inContAlert, FibreCoat, DieEnergiekoppler und RECTECH ausgezeichnet. Die Online-Messe der Science4Life TechWEEK mit 70 Ausstellern läuft noch bis zum 16. Mai. Frankfurt am Main, 12. Mai 2021. Beim digitalen Science4Life TechSLAM pitchten 20 Start-up-Teams um die Gunst des Publikums. Statt um Fachjargon und harte Fakten ging es beim TechSLAM um Kreativität und Wortwitz. Denn wer seine Idee in nur 3 Minuten am verständlichsten und einfallsreichsten erklärte, schaffte es, das Publikum von sich zu überzeugen. Die 250 Besucher wählten aus den insgesamt 20 Teams die vier besten der jeweiligen Kategorie Medizin, Material & Nachhaltigkeit, Energie, Pharma & Diagnostik aus. Die Gewinner heißen dieses Jahr: inContAlert, FibreCoat, DieEnergiekoppler und RECTECH. Besonders viel Kreativität hat das Team von Clean Ocean Coatings in den Slam gesteckt – mit dem Clownfisch Nemo und den bösen Haien als Protagonisten pitchte das Team ihre umweltfreundliche Beschichtung für Schiffe. Das Start-up FibreCoat bescherte dem Publikum hingegen einen Ohrwurm mit „Ice Ice Baby“, der von der Pitch- und Sprach-Assistentin Alexa abgespielt wurde, während DieEnergiekoppler reimten, was das Zeug hält. Der Science4Life TechSLAM ist ein Teil der Science4Life TechWEEK, die noch bis zum 16. Mai 2021 läuft. Interessierte können die Online-Messe mit 70 Ausstellern besuchen, die Keynotes und Pitches an den Ständen verfolgen, mit Start-ups, Investoren und Experten in der TechLOUNGE netzwerken oder ihr Tech-Wissen beim Sciecne4Life-Quiz unter Beweis stellen. Anmeldung unter https://science4life.expo-ip.com, die Teilnahme ist kostenlos. Diese Teams haben das Publikum überzeugt In der Kategorie Medizin gewann das Team von inContAlert. Das Produkt ist für Menschen, die unter Inkontinenz leiden und besteht aus einem Sensorsystem, das den Füllstand der Blase misst, der dann in einer App angezeigt wird. Eine unter Inkontinenz leidende Person kann so auf ihrem Handy nachschauen, wann der nächste Zeitpunkt zum Aufsuchen der Toilette ist. Den Preis im Bereich Material & Nachhaltigkeit sicherte sich das Team von FibreCoat. Das Start-up hat ein patentiertes Verfahren entwickelt, das den Preis von Verbundfasern um 90 % reduziert und die herausragenden Eigenschaften dieser Werkstoffgruppe für Massenanwendungen verfügbar macht. Den besten Pitch in der Rubrik Energie präsentierte das Team von DieEnergiekoppler GmbH. Das Unternehmen bietet mit seinem Produkt eine hochautomatisierte Systemlösung zur kostengünstigen Vernetzung, Aggregation und Flexibilitätsmanagement von kleinen bis großen Energieanlagen. In Pharma & Diagnostik begeisterte das Team von RECTECH. Das Start-up entwickelt hochpräzise Designer-Rekombinasen zur Behandlung von genetisch bedingten Erkrankungen. Mit dieser speziellen Technologie eröffnet RECTECH die Möglichkeit, maßgeschneiderte Behandlungstherapien zu entwickeln.

BOHEMIA, N.Y. and PITTSBURGH, April 30, 2021 /PRNewswire/ -- Scientific Industries, Inc. (OTCQB: SCND), a life sciences tool provider, and a developer of optical sensors for non-invasive, real-time monitoring of cell culture systems through its subsidiary Scientific Bioprocessing, Inc. ("SBI"), today announced its acquisition of aquila biolabs GmbH, a privately held German technology developer of smart sensors and state-of-the-art data analytics software for bioprocessing applications under agreed upon terms. The Company believes the acquisition positions the Company to become a leading player in the bioprocessing industry. John Moore, SBI's President and Chairman of Scientific Industries, said, "The combined technologies from these two companies will allow us to create a new digital platform that brings dramatic innovation and significantly enhance accuracy in and throughput to the biopharmaceutical workflow. We now have a target cell culture and biomanufacturing market that approximates $1.2 billion annually that has almost no digital technology to increase productivity. The ability to precisely tune multiple culture parameters is essential for efficient, consistent production of high-quality therapeutics. We believe we are well positioned to capture market share in the coming years and are excited about the opportunities ahead." The synergy of technologies developed by SBI and aquila biolabs for real-time, non-invasive cell monitoring positions the combined organization to advance a digital, sensor-based platform to optimize, simplify and accelerate bioprocessing workflows. Once developed, the platform will enable online, real-time monitoring of bioprocessing parameters delivering insights and actionable data needed to develop and maintain precisely defined and tightly controlled workflows that will improve time-to-market and digitally simplify bioprocessing. The platform will be compatible with a broad variety of bench- and production-scale vessels, transforming them into data factories that can fuel state-of-the-art machine learning and AI tools. "As SBI explored the breadth of available technologies that could spearhead digitally simplified bioprocessing, aquila's approach stood out as the most impressive one," said Reinhard Vogt, Chairman of SBI and former Executive Vice President and Member of the Board of Sartorius AG. "In addition to a strong pipeline of advanced sensors and data analytics tools, this strategic acquisition adds new talent to our already strong team and expands SBI's footprint into Europe." In connection with the acquisition, aquila biolabs has entered into new contracts with its four founders and with Daniela Winzker-Demes, industry veteran and former Vice President of Sales EMEA at Sartorius Lab Instruments, as SBI's Vice President of Sales EMEA and Asia. "We are excited to join SBI and expand the reach of our unique platform to bioprocess scientists around the world," said Daniel Grünes, co-founder of aquila biolabs who will assume the role of vice president of R&D and Operations at SBI. "While customers already have access to some process parameters, there are still too many black boxes and unknowns in bioprocessing. Our platform combined with SBI will deliver actionable insights to our customers to help them make the right decisions." "The successful acquisition of aquila biolabs is one more step in our Company's path to becoming a world class life sciences tool provider and an international company," said Helena Santos, CEO of Scientific Industries. KeyBanc Capital Markets acted as financial advisor to the Company in the acquisition of aquila biolabs. The Company financed the acquisition of aquila biolabs through an equity private placement. KeyBanc Capital Markets acted as sole placement agent on the transaction.   About aquila Biolabs aquila biolabs is a German life science company focusing on the development of innovative smart sensors and state-of-the-art data analytics software for bioprocessing applications. The company was founded in 2014 in Aachen and received the EXIST scholarship from the German Federal Ministry for Economic Affairs and Energy. In 2015, aquila biolabs closed a seven-digit seed investment, followed by a seven-digit Pre-Series A investment in 2018 from its investors, the Seed Fonds Aachen II, the KfW Bankengruppe, the Qiagen co-founder Dr. Jürgen Schumacher as well as Robert Huber, a professor for bioprocess engineering. About Scientific Bioprocessing, Inc.SBI is dedicated to providing state-of-the-art instruments, strategies, and technologies to expedite the production of viable cells and therapies with a streamlined process and product consistency. SBI's mission is to develop sensor technologies and instruments that make cell culture and bioprocessing work easier, experiments more reproducible, and culture conditions better suited to meet experimental objectives. SBI is a subsidiary of Scientific Industries, Inc. To learn more, visit www.scientificbio.com. About Scientific Industries, Inc.Scientific Industries (OTCQB:SCND), is a life science tool provider. It designs, manufactures, and markets laboratory equipment, including the world-renowned Vortex-Genie® 2 Mixer and Torbal® balances, and bioprocessing systems and methods. Scientific Industries' products are generally used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies. To learn more, visit www.scientificindustries.com. Safe Harbor StatementStatements made in this press release that relate to future events, performance or financial results of the Company are forward-looking statements which involve uncertainties that could cause actual events, performance or results to materially differ. The Company undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statement should be read in conjunction with the additional information about risks and uncertainties set forth in the Company's Securities and Exchange Commission reports, including our annual report on Form 10-K. Contact aquila Biolabs: Jens Bayer VP Marketing jens.bayer@aquila-biolabs.de +49 163 2922615 Contact Scientific Bioprocessing:Sandy WilliamsMarketing and Product ManagerScientific Bioprocessing, Inc.412-230-8463media@scientificbio.comwww.scientificbio.com